Rochester, NY 7/31/2009 7:12:57 PM
Schering-Plough cp, SGP - Supported by US FDA with Antipsychotic Drug
SCHERING PLOUGH CP
SCHERING PLOUGH CP, SGP
WhisperFromWallStreet.com offers daily stock alerts to subscribers. Sign up for our free alerts newsletter.
A U.S. medical advisory panel on Thursday widely supported Schering-Plough Corp's experimental drug, Saphris, as a secure and effective therapy for adults with acute schizophrenia and a more severe type of bipolar disorder. The Food and Drug Administration's outside advisers unanimously backed the antipsychotic medication's use in treating mania in patients with bipolar I disorder, and most also backed its use for those with schizophrenia.
Schering, which is predictable to be acquired by Merck & Co Inc later this year, is seeking the agency's approval to market the drug as another treatment option for patients with either mood illness and has said Saphris could earn more than $1 billion a year. Although there are already a number of other available medications, "we still could use more options for treating both these challenging populations," said panel member Andrew Winokur, a psychiatrist at the University of Connecticut School of Medicine.
About WhisperFromWallStreet.com
WhisperfromWallStreet.com is a FREE award winning newsletter that specializes in sending alerts to our subscribers on stocks we think are going to run, why we think so, as well as teaching you how to become a better trader. We scan hundreds of stocks a day to find those that meet our criteria and when we find one, we send you an alert.
Sign up for our FREE alerts newsletter at WhisperfromWallStreet.com
Disclaimer: Full disclaimer at http://whisperfromwallstreet.com/disclaimer.php
